| 1 Pain on weight bearing (0‐100 mm VAS) |
6 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.1 1 to 4 weeks post‐injection |
6 |
481 |
Mean Difference (IV, Random, 95% CI) |
‐12.54 [‐20.39, ‐4.69] |
| 1.2 5 to 13 weeks post‐injection |
5 |
385 |
Mean Difference (IV, Random, 95% CI) |
‐22.46 [‐35.24, ‐9.68] |
| 1.3 14 to 26 weeks post‐injection |
4 |
301 |
Mean Difference (IV, Random, 95% CI) |
‐20.70 [‐35.56, ‐5.83] |
| 2 Pain walking (0‐100 mm VAS) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2.1 1 to 4 weeks post‐injection |
2 |
124 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.96 [‐9.01, 1.10] |
| 2.2 5 to 13 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
‐13.80 [‐19.74, ‐7.86] |
| 3 WOMAC pain |
3 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 1 to 4 weeks post‐injection |
2 |
60 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐1.26 [‐1.86, ‐0.66] |
| 3.2 5 to 13 weeks post‐injection |
3 |
170 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.69 [‐1.02, ‐0.36] |
| 3.3 14 to 26 weeks post‐injection |
1 |
30 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐1.09 [‐1.92, ‐0.25] |
| 4 Pain at night (0‐100 mm VAS) |
6 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4.1 1 to 4 weeks post‐injection |
6 |
391 |
Mean Difference (IV, Fixed, 95% CI) |
‐8.03 [‐11.95, ‐4.12] |
| 4.2 5 to 13 weeks post‐injection |
5 |
295 |
Mean Difference (IV, Fixed, 95% CI) |
‐14.47 [‐18.57, ‐10.38] |
| 4.3 14 to 26 weeks post‐injection |
3 |
182 |
Mean Difference (IV, Fixed, 95% CI) |
‐17.12 [‐23.22, ‐11.02] |
| 5 Pain at rest (0‐100 mm VAS) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.1 1 to 4 weeks post‐injection |
2 |
124 |
Mean Difference (IV, Fixed, 95% CI) |
‐9.44 [‐14.07, ‐4.82] |
| 5.2 5 to 13 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
‐18.67 [‐23.32, ‐14.02] |
| 6 Pain overall (0‐100 mm VAS) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 6.1 1 to 4 weeks post‐injection |
1 |
94 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.0 [‐13.09, 9.09] |
| 7 WOMAC physical function |
3 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 7.1 1 to 4 weeks post‐injection |
2 |
60 |
Mean Difference (IV, Fixed, 95% CI) |
‐7.09 [‐10.62, ‐3.56] |
| 7.2 5 to 13 weeks post‐injection |
3 |
170 |
Mean Difference (IV, Fixed, 95% CI) |
‐11.91 [‐15.06, ‐8.76] |
| 7.3 14 to 26 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
‐17.0 [‐26.90, ‐7.10] |
| 8 Lequesne Index (0‐24) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 8.1 5 to 13 weeks post‐injection |
1 |
110 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.60 [‐2.98, ‐0.22] |
| 8.2 14 to 26 weeks post‐injection |
1 |
154 |
Mean Difference (IV, Fixed, 95% CI) |
0.10 [‐1.38, 1.58] |
| 9 Function: improvment in most painful knee movement (0‐100 mm VAS) |
4 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 9.1 1 to 4 weeks post‐injection |
4 |
267 |
Mean Difference (IV, Fixed, 95% CI) |
19.29 [12.26, 26.31] |
| 9.2 5 to 13 weeks post‐injection |
4 |
263 |
Mean Difference (IV, Fixed, 95% CI) |
33.25 [26.18, 40.31] |
| 10 15 metre walking time |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 10.1 1 to 4 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
0.80 [‐0.61, 2.21] |
| 10.2 5 to 13 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.87 [‐2.52, 0.78] |
| 11 WOMAC stiffness (2 to 10 Likert) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 11.1 1 to 4 weeks post‐injection |
2 |
60 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.08 [‐1.73, ‐0.44] |
| 11.2 5 to 13 weeks post‐injection |
2 |
60 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.34 [‐2.13, ‐0.55] |
| 11.3 14 to 26 weeks post‐injection |
1 |
39 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.0 [‐1.89, ‐0.11] |
| 12 Patient global assessment (0‐100 mm VAS; where 100 is worst severity) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 12.1 1 to 4 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
‐20.0 [‐33.16, ‐6.84] |
| 12.2 5 to 13 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
‐20.0 [‐30.57, ‐9.43] |
| 12.3 14 to 26 weeks post injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [‐12.68, 12.68] |
| 13 Patient global assessment (number of patients good or very good) 5 to 13 weeks post‐injection |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 14 Patient global evaluation of efficacy due to treatment |
5 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 14.1 1 to 4 weeks post‐injection |
5 |
298 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.70 [0.46, 0.93] |
| 14.2 5 to 13 weeks post‐injection |
5 |
295 |
Std. Mean Difference (IV, Fixed, 95% CI) |
1.23 [0.97, 1.48] |
| 15 Physician global assessment (0‐100 mm VAS; where 100 is worst severity) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.1 1 to 4 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
‐20.0 [‐37.64, ‐2.36] |
| 15.2 5 to 13 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
‐20.0 [‐36.10, ‐3.90] |
| 15.3 14 to 26 weeks post injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
‐10.00 [‐26.38, 6.38] |
| 16 Number of survivors (patients not requiring additional treatment for study knee) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 16.1 45 to 52 weeks post‐injection |
1 |
152 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.33 [0.87, 2.01] |
| 17 Number of clinical failures |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 17.1 14 to 26 weeks post‐injection |
1 |
152 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.66 [0.23, 1.87] |
| 17.2 45 to 52 weeks post‐injection |
1 |
118 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.84 [0.59, 1.22] |
| 18 Need for paracetamol (pill count) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 18.1 1 to 4 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 18.2 5 to 13 weeks post‐injection |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 19 Safety: total withdrawals overall |
6 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 19.1 1 to 4 weeks post‐injection |
1 |
94 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.70 [0.12, 3.97] |
| 19.2 5 to 13 weeks post‐injection |
4 |
329 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.40 [0.64, 3.06] |
| 19.3 14 to 26 weeks post‐injection |
1 |
52 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.63 [0.24, 1.66] |
| 20 Safety: number of patients withdrawn due to noncomplinance |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 21 Safety: number of patients with local reaction |
6 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 22 Safety: number of patients with local adverse reactions but study drug continued |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 22.1 1 to 4 weeks post‐injection |
1 |
30 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.13, 68.26] |
| 23 Safety: number of patients with one or more probable or possible related systemic adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 23.1 5 to 13 weeks post‐injection |
1 |
104 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.98 [0.79, 4.96] |
| 24 Safety: number of patients reporting systemic reactions |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 24.1 5 to 13 weeks post‐injection |
3 |
219 |
Risk Ratio (M‐H, Fixed, 95% CI) |
7.36 [0.39, 139.44] |
